These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 29777191)

  • 1. Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter.
    Shimizu K; Soroida Y; Sato M; Hikita H; Kobayashi T; Endo M; Sato M; Gotoh H; Iwai T; Tateishi R; Koike K; Yatomi Y; Ikeda H
    Sci Rep; 2018 May; 8(1):7845. PubMed ID: 29777191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication.
    Chromy D; Mandorfer M; Bucsics T; Schwabl P; Bauer D; Scheiner B; Schmidbauer C; Lang GF; Szekeres T; Ferenci P; Trauner M; Reiberger T
    AIDS Patient Care STDS; 2019 May; 33(5):197-206. PubMed ID: 31067123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
    Kawagishi N; Suda G; Nakamura A; Kimura M; Maehara O; Suzuki K; Nakamura A; Ohara M; Izumi T; Umemura M; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Kudo Y; Nishida M; Miyoshi H; Sakamoto N
    PLoS One; 2018; 13(12):e0209615. PubMed ID: 30576386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals.
    Noureddin M; Wong MM; Todo T; Lu SC; Sanyal AJ; Mena EA
    World J Gastroenterol; 2018 Mar; 24(11):1269-1277. PubMed ID: 29568207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
    Kobayashi N; Iijima H; Tada T; Kumada T; Yoshida M; Aoki T; Nishimura T; Nakano C; Takata R; Yoh K; Ishii A; Takashima T; Sakai Y; Aizawa N; Nishikawa H; Ikeda N; Iwata Y; Enomoto H; Hirota S; Fujimoto J; Nishiguchi S
    Eur J Gastroenterol Hepatol; 2018 May; 30(5):546-551. PubMed ID: 29494353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a.
    Hofer H; Bankl HC; Wrba F; Steindl-Munda P; Peck-Radosavljevic M; Osterreicher C; Mueller C; Gangl A; Ferenci P
    Am J Gastroenterol; 2002 Nov; 97(11):2880-5. PubMed ID: 12425563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar prevalence of hepatic steatosis among patients with chronic hepatitis C with and without HIV coinfection.
    Fernandez-Fuertes M; Macías J; Corma-Gómez A; Rincón P; Merchante N; Gómez-Mateos J; Pineda JA; Real LM
    Sci Rep; 2020 Apr; 10(1):6736. PubMed ID: 32317646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy.
    Tada T; Kumada T; Toyoda H; Sone Y; Takeshima K; Ogawa S; Goto T; Wakahata A; Nakashima M; Nakamuta M; Tanaka J
    Aliment Pharmacol Ther; 2018 Apr; 47(7):1012-1022. PubMed ID: 29424449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
    Ogasawara N; Kobayashi M; Akuta N; Kominami Y; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Suzuki F; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2018 Feb; 90(2):313-319. PubMed ID: 28906010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP).
    Cespiati A; Petta S; Lombardi R; Di Marco V; Calvaruso V; Bertelli C; Pisano G; Fatta E; Sigon G; Iuculano F; Crapanzano L; Gibilaro G; Francione P; Craxì A; Fargion S; Fracanzani AL
    Dig Liver Dis; 2021 Oct; 53(10):1301-1307. PubMed ID: 33214063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis.
    Castéra L; Hézode C; Roudot-Thoraval F; Lonjon I; Zafrani ES; Pawlotsky JM; Dhumeaux D
    Gut; 2004 Mar; 53(3):420-4. PubMed ID: 14960527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication.
    Huang CF; Dai CY; Yeh ML; Huang CI; Lee HC; Lai WT; Liang PC; Lin YH; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Huang JF; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2020 Nov; 36(11):920-928. PubMed ID: 32643842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C.
    Adinolfi LE; Utili R; Andreana A; Tripodi MF; Marracino M; Gambardella M; Giordano M; Ruggiero G
    Dig Dis Sci; 2001 Aug; 46(8):1677-83. PubMed ID: 11508667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C.
    Tachi Y; Katano Y; Honda T; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Samejima Y; Goto H
    Liver Int; 2010 Apr; 30(4):554-9. PubMed ID: 19951380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of HCV Eradication after Direct-Acting Antiviral Agents on Hepatic Steatosis: A Prospective Observational Study.
    Soliman H; Ziada D; Hamisa M; Badawi R; Hawash N; Salama M; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2022; 22(1):100-107. PubMed ID: 33550979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum lipid profile and hepatic steatosis of adult beta-thalassaemia patients with chronic HCV infection.
    Siagris D; Kouraklis-Symeonidis A; Christofidou M; Lekkou A; Papadimitriou C; Arvaniti V; Thomopoulos K; Tsamandas A; Zoumbos N; Labropoulou-Karatza C
    Eur J Gastroenterol Hepatol; 2005 Mar; 17(3):345-50. PubMed ID: 15716660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of treatment with direct acting antivirals on body mass index and hepatic steatosis in chronic hepatitis C.
    Shousha HI; Abdelaziz RA; Azab SM; Khairy M; Afifi SA; Mehrez MI; Eshra MA; Abdelrahim AY
    J Med Virol; 2018 Jun; 90(6):1099-1105. PubMed ID: 29469217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.
    Petit JM; Benichou M; Duvillard L; Jooste V; Bour JB; Minello A; Verges B; Brun JM; Gambert P; Hillon P
    Am J Gastroenterol; 2003 May; 98(5):1150-4. PubMed ID: 12809841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
    Beig J; Orr D; Harrison B; Gane E
    Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
    Westin J; Lagging M; Dhillon AP; Norkrans G; Romero AI; Pawlotsky JM; Zeuzem S; Schalm SW; Verheij-Hart E; Negro F; Missale G; Neumann AU; Hellstrand K;
    J Viral Hepat; 2007 Jan; 14(1):29-35. PubMed ID: 17212641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.